Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The AGILE trial demonstrated significant improvements in event-free survival and overall survival for ivosidenib plus azacitidine compared to azacitidine plus placebo, with hazard ratios of 0.33 and 0.42 respectively. However, the lack of direct comparison with the standard of care (venetoclax plus azacitidine) limits the strength of the evidence.
Cost effectiveness
The cost-effectiveness estimates for ivosidenib plus azacitidine are within the acceptable range for Healthcare resources, with an ICER under £30,000 per QALY gained, indicating marginal cost-effectiveness.
Quality of life
While the document discusses the potential benefits of ivosidenib plus azacitidine, it does not provide specific data on HRQoL improvements or validated tools measuring these outcomes, leading to a conclusion of minimal or mixed impact.
Supporting Domains
Safety and Adverse Effects
The safety profile of ivosidenib plus azacitidine is considered very good, with manageable adverse events reported in the AGILE trial, which is comparable to existing therapies.
Comparator Selection
The primary comparator, venetoclax plus azacitidine, was not directly tested against ivosidenib plus azacitidine, leading to reliance on indirect comparisons which introduces uncertainty.
Patient Population and Subgroups
The trial population is representative of the intended patient population with untreated AML and IDH1 mutations, although there are some limitations in subgroup analyses.
Care Pathway Integration
Ivosidenib plus azacitidine can be integrated into existing treatment pathways with minor adjustments, as it is an oral treatment option that is preferable to intravenous therapies.
Resource Use and Cost Implications
The economic model indicates manageable budget impact and resource use, with the potential for cost savings due to reduced hospital stays and transfusion needs.
Evidence Quality and Robustness
The evidence is based on a Phase 3 RCT (AGILE trial) with a robust design, although there are some concerns regarding the indirect comparisons and the potential for bias.
Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term outcomes and the assumptions made in the economic model, particularly concerning the cure assumption and the generalizability of results.
